# Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

> **NCT06837922** · PHASE3 · RECRUITING · sponsor: **Shanghai Mabgeek Biotech.Co.Ltd** · enrollment: 504 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MG-K10/Placebo

## Key facts

- **NCT ID:** NCT06837922
- **Lead sponsor:** Shanghai Mabgeek Biotech.Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2027-11-15
- **Final completion:** 2028-01-15
- **Target enrollment:** 504 (ESTIMATED)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06837922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06837922, "Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06837922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*